GlassScriptPhysician profile
Tejas I Patel
NPI 1437125770
$11,605.18
in general payments reported to CMS, 2019-2025
66 companies · $2,093 in 2025
The $2,093 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,307 · 2020: $1,273 · 2021: $1,395 · 2022: $1,804 · 2023: $2,161 · 2024: $1,573 · 2025: $2,093.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,807 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,807.27 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,033.70 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $879.20 | 2019-2025 | Jardiance, Tradjenta |
| Novartis Pharmaceuticals Corporation | $843.46 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $837.31 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $744.73 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $727.14 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $691.56 | 2021-2025 | |
| Amgen INC. | $533.03 | 2019-2025 | Repatha, Otezla, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $400.87 | 2021-2025 | |
| Astellas Pharma US INC | $327.27 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $285.97 | 2019-2025 | Eliquis, Camzyos |
| Boston Scientific Corporation | $272.21 | 2019-2023 | |
| Dexcom, INC. | $257.13 | 2021-2025 | Dexcom G6 Transmitter |
| Pfizer INC. | $254.03 | 2019-2024 | |
| Gilead Sciences, INC. | $203.94 | 2019-2023 |
Show all 66 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tejas Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.